Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies1

Biochemistry and Cell Biology

Volumn 93, Issue 5, 2015, Pages 479-486

  Chang, Wenguang ^a   Chen, Li ^b   Hatch, Grant M ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Basic Medical College   (China)

Author keywords

Adenosine 5 monophosphate kinase; Adults; Berberine; Children; Complications; Drug; Hypoglycemic; Metabolism; Type 2 diabetes mellitus

Indexed keywords

DISEASES; METABOLISM; PATIENT TREATMENT;

ADULTS; BERBERINE; CHILDREN; COMPLICATIONS; DRUG; HYPOGLYCEMIC; MONOPHOSPHATES; TYPE 2 DIABETES MELLITUS;

DISEASE CONTROL;

BERBERINE; ANTIDIABETIC AGENT;

ANTIDIABETIC ACTIVITY; BRADYCARDIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); CONSTIPATION; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIARRHEA; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; HEADACHE; HUMAN; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SKIN IRRITATION; VOMITING; ANIMAL; COMPLICATION; DIABETES MELLITUS, TYPE 2;

ANIMALS; BERBERINE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84984895739     PISSN: 08298211     EISSN: 12086002     Source Type: Journal    
DOI: 10.1139/bcb-2014-0107     Document Type: Review

References (94)

1. American Diabetes Association 2014. Standards of Medical Care in Diabetes-2014. Diabetes Care, 37 (Suppl. 1): S14-S80. 10.2337/dc14-S014.
2. Affuso F. Mercurio V. Fazio V. Fazio S. 2010. Cardiovascular and metabolic effects of Berberine. World J. Cardiol. 2 (4): 71-77. 10.4330/wjc.v2.i4.71. 21160701.
3. Arslanian S. 2002. Type 2 diabetes in children: clinical aspects and risk factors. Horm. Res. 57 (Suppl. 1): 19-28. 10.1159/000053308. 11979018.
4. Cannillo M. Frea S. Fornengo C. Toso E. Mercurio G. Battista S. Gaita F. 2013. Berberine behind the thriller of marked symptomatic bradycardia. World J. Cardiol. 5 (7): 261-264. 10.4330/wjc.v5.i7.261. 23888197.
5. Chan E. 1993. Displacement of bilirubin from albumin by berberine. Biol. Neonate, 63 (4): 201-208. 10.1159/000243932. 8513024.
6. Chang W. Zhang M. Li J. Meng Z. Xiao D. Wei S. et al 2012. Berberine attenuates ischemia-reperfusion injury via regulation of adenosine-5′-monophosphate kinase activity in both non-ischemic and ischemic areas of the rat heart. Cardiovasc. Drugs Ther. 26 (6): 467-478. 10.1007/s10557-012-6422-0. 23179953.
7. Chang W. Zhang M. Li J. Meng Z. Wei S. Du H. et al 2013. Berberine improves insulin resistance in cardiomyocytes via activation of 5′-adenosine monophosphate-activated protein kinase. Metabolism, 62 (8): 1159-1167. 10.1016/j.metabol.2013.02.007. 23537779.
8. Chauhan R.K. Jain A.M. Bhandari B. 1970. Berberine in the treatment of childhood diarrhoea. Indian J. Pediatr. 37 (274): 577-579. 10.1007/BF02803833. 5518228.
9. Cheng F. Wang Y. Li J. Su C. Wu F. Xia W.H. et al 2013. Berberine improves endothelial function by reducing endothelial microparticles-mediated oxidative stress in humans. Int. J. Cardiol. 167 (3): 936-942. 10.1016/j.ijcard.2012.03.090. 22465347.
10. Cheng Z. Pang T. Gu M. Gao A.H. Xie C.M. Li J.Y. et al 2006. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim. Biophys. Acta, 1760 (11): 1682-1689. 10.1016/j.bbagen.2006.09.007. 17049164.
11. Del Rio D. Stewart A.J. Pellegrini N. 2005. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr. Metab. Cardiovasc Dis. 15 (4): 316-328. 10.1016/j.numecd.2005.05.003. 16054557.
12. Derosa G. D'Angelo A. Bonaventura A. Bianchi L. Romano D. Maffioli P. 2013. Effects of berberine on lipid profile in subjects with low cardiovascular risk. Expert Opin. Biol. Ther. 13 (4): 475-482. 10.1517/14712598.2013.776037. 23441841.
13. Di Pierro F. Villanova N. Agostini F. Marzocchi R. Soverini V. Marchesini G. 2012. Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab. Syndr. Obes. 5: 213-217. 10.2147/DMSO.S33718. 22924000.
14. Di Pierro F. Putignano P. Villanova N. Montesi L. Moscatiello S. Marchesini G. 2013. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin. Pharmacol. 5: 167-174. 10.2147/CPAA.S54308. 24277991.
15. Dorota Zozulinska B.W.-W. 2006. Type 2 diabetes mellitus as inflammatory disease. Diabetes Res. Clin. Pract. 74 (Suppl.): S12-S16. 10.1016/j.diabres.2006.06.007.
16. Evans J.L. Maddux B.A. Goldfine I.D. 2005. The molecular basis for oxidative stress-induced insulin resistance. Antioxid. Redox Signal. 7 (7-8): 1040-1052. 10.1089/ars.2005.7.1040. 15998259.
17. Gomes A.P. Duarte F.V. Nunes P. Hubbard B.P. Teodoro J.S. Varela A.T. et al 2012. Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. Biochim. Biophys. Acta, 1822 (2): 185-195. 10.1016/j.bbadis.2011.10.008. 22027215.
18. GPAC. 2010. Diabetes Care. Guidlines and protocols.: Guidelines and Protocols Advisory Committee.
19. Gray S.P. Di Marco E. Okabe J. Szyndralewiez C. Heitz F. Montezano A.C. et al 2013. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation, 127 (18): 1888-1902. 10.1161/CIRCULATIONAHA.112.132159. 23564668.
20. Guariguata L. Whiting D.R. Hambleton I. Beagley J. Linnenkamp U. Shaw J.E. 2014. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 103 (2): 137-149. 10.1016/j.diabres.2013.11.002. 24630390.
21. Hsu Y.Y. Chen C.S. Wu S.N. Jong Y.J. Lo Y.C. 2012. Berberine activates Nrf2 nuclear translocation and protects against oxidative damage via a phosphatidylinositol 3-kinase/Akt-dependent mechanism in NSC34 motor neuron-like cells. Eur. J. Pharm. Sci. 46 (5): 415-425. 10.1016/j.ejps.2012.03.004. 22469516.
22. Hu Y. Davies G.E. 2010. Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. Fitoterapia, 81 (5): 358-366. 10.1016/j.fitote.2009.10.010. 19861153.
23. Huang C. Zhang Y. Gong Z. Sheng X. Li Z. Zhang W. Qin Y. 2006. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARgamma pathway. Biochem. Biophys. Res. Commun. 348 (2): 571-578. 10.1016/j.bbrc.2006.07.095. 16890192.
24. Huynh K. Kiriazis H. Du X.J. Love J.E. Gray S.P. Jandeleit-Dahm K.A. et al 2013. Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice. Free Radic. Biol. Med. 60: 307-317. 10.1016/j.freeradbiomed.2013.02.021. 23454064.
25. Jiang Q. Liu P. Wu X. Liu W. Shen X. Lan T. et al 2011. Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-kappaB signaling pathway. Mol. Cell. Endocrinol. 331 (1): 34-40. 10.1016/j.mce.2010.07.023. 20674665.
26. Kajbaf F. Arnouts P. de Broe M. Lalau J.D. 2013. Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the world. Pharmacoepidemiol. Drug Saf. 22 (10): 1027-1035. 10.1002/pds.3501. 23960029.
27. Kalalian-Moghaddam H. Baluchnejadmojarad T. Roghani M. Goshadrou F. Ronaghi A. 2013. Hippocampal synaptic plasticity restoration and anti-apoptotic effect underlie berberine improvement of learning and memory in streptozotocin-diabetic rats. Eur. J. Pharmacol. 698 (1-3): 259-266. 10.1016/j.ejphar.2012.10.020. 23099256.
28. Kalra S. 2013. Paediatric diabetes. J. Pak. Med. Assoc. 63 (9): 1197-1200. 24601207.
29. Kaneto H. Xu G. Fujii N. Kim S. Bonner-Weir S. Weir G.C. 2002. Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. J. Biol. Chem. 277 (33): 30010-30018. 10.1074/jbc.M202066200. 12011047.
30. Khosla P.K. Neeraj V.I. Gupta S.K. Satpathy G. 1992. Berberine, a potential drug for trachoma. Rev. Int. Trach. Pathol. Ocul. Trop. Subtrop. Sante Publique, 69: 147-165. 1344968.
31. Kim S.O. Kim H.J. 2013. Berberine ameliorates cold and mechanical allodynia in a rat model of diabetic neuropathy. J. Med. Food, 16 (6): 511-517. 10.1089/jmf.2012.2648. 23734996.
32. Kim S.H. Shin E.J. Kim E.D. Bayaraa T. Frost S.C. Hyun C.K. 2007. Berberine activates GLUT1-mediated glucose uptake in 3T3-L1 adipocytes. Biol. Pharm. Bull. 30 (11): 2120-2125. 10.1248/bpb.30.2120. 17978486.
33. Kim W.S. Lee Y.S. Cha S.H. Jeong H.W. Choe S.S. Lee M.R. et al 2009. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am. J. Physiol. Endocrinol. Metab. 296 (4): E812-E819. 10.1152/ajpendo.90710.2008. 19176354.
34. Ko B.S. Choi S.B. Park S.K. Jang J.S. Kim Y.E. Park S. 2005. Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma. Biol. Pharm. Bull. 28 (8): 1431-1437. 10.1248/bpb.28.1431. 16079488.
35. Kysenius K. Brunello C.A. Huttunen H.J. 2014. Mitochondria and NMDA receptor-dependent toxicity of berberine sensitizes neurons to glutamate and rotenone injury. PLoS One, 9 (9): e107129. 10.1371/journal.pone.0107129. 25192195.
36. Lan T. Shen X. Liu P. Liu W. Xu S. Xie X. et al 2010. Berberine ameliorates renal injury in diabetic C57BL/6 mice: Involvement of suppression of SphK-S1P signaling pathway. Arch. Biochem. Biophys. 502 (2): 112-120. 10.1016/j.abb.2010.07.012. 20646989.
37. Lan T. Liu W. Xie X. Huang K. Peng J. Huang J. et al 2012. Berberine suppresses high glucose-induced TGF-beta1 and fibronectin synthesis in mesangial cells through inhibition of sphingosine kinase 1/AP-1 pathway. Eur. J. Pharmacol. 697 (1-3): 165-172. 10.1016/j.ejphar.2012.10.003. 23085271.
38. Lee C.H. Chen J.C. Hsiang C.Y. Wu S.L. Wu H.C. Ho T.Y. 2007 a. Berberine suppresses inflammatory agents-induced interleukin-1beta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells. Pharmacol. Res. 56 (3): 193-201. 10.1016/j.phrs.2007.06.003. 17681786.
39. Lee S. Lim H.J. Park J.H. Lee K.S. Jang Y. Park H.Y. 2007 b. Berberine-induced LDLR up-regulation involves JNK pathway. Biochem. Biophys. Res. Commun. 362 (4): 853-857. 10.1016/j.bbrc.2007.08.060. 17767919.
40. Lee Y.S. Kim W.S. Kim K.H. Yoon M.J. Cho H.J. Shen Y. et al 2006. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes, 55 (8): 2256-2264. 10.2337/db06-0006. 16873688.
41. Leng S.H. Lu F.E. Xu L.J. 2004. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol. Sin. 25 (4): 496-502. 15066220.
42. Li J.M. Shah A.M. 2003. ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J. Am. Soc. Nephrol. 14 (8 Suppl. 3): S221-S226. 10.1097/01.ASN.0000077406.67663.E7. 12874435.
43. Li Y. Ma H. Zhang Y. Kuang H. Ng E.H. Hou L. Wu X. 2013. Effect of berberine on insulin resistance in women with polycystic ovary syndrome: study protocol for a randomized multicenter controlled trial. Trials, 14: 226. 10.1186/1745-6215-14-226. 23866924.
44. Lin T.Y. Lin Y.W. Lu C.W. Huang S.K. Wang S.J. 2013. Berberine Inhibits the Release of Glutamate in Nerve Terminals from Rat Cerebral Cortex. PLoS One, 8 (6): e67215. 10.1371/journal.pone.0067215. 23840629.
45. Linn Y.C. Lu J. Lim L.C. Sun H. Sun J. Zhou Y. Ng H.S. 2012. Berberine-induced haemolysis revisited: safety of Rhizoma coptidis and Cortex phellodendri in chronic haematological diseases. Phytother. Res. 26 (5): 682-686. 10.1002/ptr.3617. 22002596.
46. Lu S.S. Yu Y.L. Zhu H.J. Liu X.D. Liu L. Liu Y.W. Wang P. Xie L. Wang G.J. 2009. Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats. J. Endocrinol. 200 (2): 159-165. 10.1677/JOE-08-0419. 18996945.
47. Mahajan V.M. Mohan M. 1985. Development of a macromolecular vaccine against experimental chlamydiosis and berberine-a new anti-trachoma agent. Rev. Int. Trach. Pathol. Ocul. Trop. Subtrop. Sante Publique, 62 (1-2): 103-116. 3842892.
48. Marazzi G. Cacciotti L. Pelliccia F. Iaia L. Volterrani M. Caminiti G. et al 2011. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv. Ther. 28 (12): 1105-1113. 10.1007/s12325-011-0082-5. 22113535.
49. Marin-Neto J.A. Maciel B.C. Secches A.L. Gallo Junior L. 1988. Cardiovascular effects of berberine in patients with severe congestive heart failure. Clin. Cardiol. 11 (4): 253-260. 10.1002/clc.4960110411. 3365876.
50. Meng Z. Zhang M. Wei S. Bi X. Hatch G.M. Gu J. Chen L. 2014. Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability. Int. J. Pharm. 467 (1-2): 50-59. 10.1016/j.ijpharm.2014.03.017. 24607213.
51. Mo C. Wang L. Zhang J. Numazawa S. Tang H. Tang X. et al 2014. The crosstalk between Nrf2 and AMPK signal pathways is important for the anti-inflammatory effect of berberine in LPS-stimulated macrophages and endotoxin-shocked mice. Antioxid. Redox Signal. 20 (4): 574-588. 10.1089/ars.2012.5116. 23875776.
52. Mohan M. Pant C.R. Angra S.K. Mahajan V.M. 1982. Berberine in trachoma. (A clinical trial). Indian J. Ophthalmol. 30 (2): 69-75. 6754599.
53. Narasimhan S. Weinstock R.S. 2014. Youth-onset type 2 diabetes mellitus: lessons learned from the TODAY study. Mayo Clin. Proc. 89 (6): 806-816. 10.1016/j.mayocp.2014.01.009. 24702733.
54. Pan G.Y. Huang Z.J. Wang G.J. Fawcett J.P. Liu X.D. Zhao X.C. et al 2003. The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption. Planta Med. 69 (7): 632-636. 10.1055/s-2003-41121. 12898419.
55. Perez-Rubio K.G. Gonzalez-Ortiz M. Martinez-Abundis E. Robles-Cervantes J.A. Espinel-Bermudez M.C. 2013. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab. Syndr. Relat. Disord. 11 (5): 366-369. 10.1089/met.2012.0183. 23808999.
56. Pham T.P. Kwon J. Shin J. 2011. Berberine exerts anti-adipogenic activity through up-regulation of C/EBP inhibitors, CHOP and DEC2. Biochem. Biophys. Res. Commun. 413 (2): 376-382. 10.1016/j.bbrc.2011.08.110. 21893041.
57. Pinhas-Hamiel O. Zeitler P. 2007. Clinical presentation and treatment of type 2 diabetes in children. Pediatr. Diabetes, 8 (Suppl. 9): 16-27. 10.1111/j.1399-5448.2007.00330.x. 17991129.
58. Pulgaron E.R. Delamater A.M. 2014. Obesity and type 2 diabetes in children: epidemiology and treatment. Curr. Diab. Rep. 14 (8): 508. 10.1007/s11892-014-0508-y. 24919749.
59. Rosen E.D. MacDougal O.A. 2006. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 7 (12): 885-896. 10.1038/nrm2066. 17139329.
60. Rosen P. Nawroth P.P. King G. Moller W. Tritschler H.J. Packer L. 2001. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab. Res. Rev. 17 (3): 189-212. 10.1002/dmrr.196. 11424232.
61. Rosenbloom, A.L., Silverstein, J.H., Amemiya, S., Zeitler, P., Maahs, D.M., and Klingensmith, G.J. 2011. Type 2 diabetes. IDF-ISPAD Diabetes in Childhood and Adolescence Guidelines 2011.
62. Sabir M. Bhide N.K. 1971. Study of some pharmacological actions of berberine. Indian J. Physiol. Pharmacol. 15 (3): 111-132. 4109503.
63. Sarna L.K. Wu N. Hwang S.Y. Siow Y.L. O K. 2010. Berberine inhibits NADPH oxidase mediated superoxide anion production in macrophages. Can. J. Physiol. Pharmacol. 88 (3): 369-378. 10.1139/Y09-136. 20393601.
64. Scheen A.J. 2014. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opin. Drug Metab. Toxicol. 10 (6): 839-857. 10.1517/17425255.2014.902444. 24669954.
65. Scivittaro V. Ganz M.B. Weiss M.F. 2000. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am. J. Physiol. Renal Physiol. 278 (4): F676-F683. 10751230.
66. Sharda D.C. 1970. Berberine in the treatment of diarrhoea of infancy and childhood. J. Indian Med. Assoc. 54 (1): 22-24. 4905644.
67. Souza B.M. Assmann T.S. Kliemann L.M. Gross J.L. Canani L.H. Crispim D. 2011. The role of uncoupling protein 2 (UCP2) on the development of type 2 diabetes mellitus and its chronic complications. Arq. Bras. Endocrinol. Metabol. 55 (4): 239-248. 10.1590/S0004-27302011000400001. 21779625.
68. Strugaru A.M. Botnariu G. Agoroaei L. Grigoriu I.C. Butnaru E. 2013. Metformin induced lactic acidosis-particularities and course. Rev. Med. Chir. Soc. Med. Nat. Iasi, 117 (4): 1035-1042. 24502087.
69. Tang L.Q. Wei W. Chen L.M. Liu S. 2006. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J. Ethnopharmacol. 108 (1): 109-115. 10.1016/j.jep.2006.04.019. 16759828.
70. Tang L. Lv F. Liu S. Zhang S. 2011. [Effect of berberine on expression of transforming growth factor-beta1 and type IV collagen proteins in mesangial cells of diabetic rats with nephropathy]. Zhongguo Zhong Yao Za Zhi, 36 (24): 3494-3497. 22368864.
71. Turner N. Li J.Y. Gosby A. To S.W. Cheng Z. Miyoshi H. et al 2008. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes, 57 (5): 1414-1418. 10.2337/db07-1552. 18285556.
72. Wang C. Li J. Lv X. Zhang M. Song Y. Chen L. Liu Y. 2009. Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. Eur. J. Pharmacol. 620 (1-3): 131-137. 10.1016/j.ejphar.2009.07.027. 19686728.
73. Wang F.L. Tang L.Q. Yang F. Zhu L.N. Cai M. Wei W. 2013. Renoprotective effects of berberine and its possible molecular mechanisms in combination of high-fat diet and low-dose streptozotocin-induced diabetic rats. Mol. Biol. Rep. 40 (3): 2405-2418. 10.1007/s11033-012-2321-5. 23196710.
74. Wang L. Li H. Wang S. Liu R. Wu Z. Wang C. et al 2014. Erratum to: Enhancing the Antitumor Activity of Berberine Hydrochloride by Solid Lipid Nanoparticle Encapsulation. AAPS PharmSciTech, 15 (5): 1355. 10.1208/s12249-014-0158-z. 24871555.
75. Wang Q. Zhang M. Liang B. Shirwany N. Zhu Y. Zou M.H. 2011. Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: the role of uncoupling protein 2. PLoS One, 6 (9): e25436. 10.1371/journal.pone.0025436. 21980456.
76. Wang Y.X. Kong W.J. Li Y.H. Tang S. Li Z. Li Y.B. et al 2012. Synthesis and structure-activity relationship of berberine analogues in LDLR up-regulation and AMPK activation. Bioorg. Med. Chem. 20 (22): 6552-6558. 10.1016/j.bmc.2012.09.029. 23058107.
77. Wu D. Wen W. Qi C.L. Zhao R.X. Lu J.H. Zhong C.Y. Chen Y.Y. 2012. Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin. Phytomedicine, 19 (8-9): 712-718. 10.1016/j.phymed.2012.03.003. 22483555.
78. Xie X. Li W. Lan T. Liu W. Peng J. Huang K. et al 2011. Berberine ameliorates hyperglycemia in alloxan-induced diabetic C57BL/6 mice through activation of Akt signaling pathway. Endocr. J. 58 (9): 761-768. 10.1507/endocrj.K11E-024. 21705841.
79. Xie X. Chang X. Chen L. Huang K. Huang J. Wang S. et al 2013. Berberine ameliorates experimental diabetes-induced renal inflammation and fibronectin by inhibiting the activation of RhoA/ROCK signaling. Mol. Cell. Endocrinol. 381 (1-2): 56-65. 10.1016/j.mce.2013.07.019. 23896433.
80. Xin H.W. Wu X.C. Li Q. Yu A.R. Zhong M.Y. Liu Y.Y. 2006. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods Find. Exp. Clin. Pharmacol. 28 (1): 25-29. 10.1358/mf.2006.28.1.962774. 16541194.
81. Xing L.J. Zhang L. Liu T. Hua Y.Q. Zheng P.Y. Ji G. 2011. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. Eur. J. Pharmacol. 668 (3): 467-471. 10.1016/j.ejphar.2011.07.036. 21839075.
82. Xue M. Yang M.X. Zhang W. Li X.M. Gao D.H. Ou Z.M. et al 2013. Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. Int. J. Nanomedicine, 8: 4677-4687. 10.2147/IJN.S51262. 24353417.
83. Yang Q.H. Hu S.P. Zhang Y.P. Xie W.N. Li N. Ji G.Y. et al 2011. Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats. Chin. J. Integr. Med. 17 (3): 205-211. 10.1007/s11655-011-0668-4. 21359922.
84. Ye M. Fu S. Pi R. He F. 2009. Neuropharmacological and pharmacokinetic properties of berberine: a review of recent research. J. Pharm. Pharmacol. 61 (7): 831-837. 10.1211/jpp.61.07.0001. 19589224.
85. Yi J. Ye X. Wang D. He K. Yang Y. Liu X. Li X. 2013. Safety evaluation of main alkaloids from Rhizoma Coptidis. J. Ethnopharmacol. 145 (1): 303-310. 10.1016/j.jep.2012.10.062. 23159469.
86. Yin J. Xing H. Ye J. 2008. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism, 57 (5): 712-717. 10.1016/j.metabol.2008.01.013. 18442638.
87. Yu Y. Liu L. Wang X. Liu X. Liu X. Xie L. Wang G. 2010. Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies. Biochem. Pharmacol. 79 (7): 1000-1006. 10.1016/j.bcp.2009.11.017. 19945441.
88. Zhan P.Y. Peng C.X. Zhang L.H. 2014. Berberine rescues D-galactose-induced synaptic/memory impairment by regulating the levels of Arc. Pharmacol. Biochem. Behav. 117: 47-51. 10.1016/j.pbb.2013.12.006. 24342459.
89. Zhang H. Wei J. Xue R. Wu J.D. Zhao W. Wang Z.Z. et al 2010. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism, 59 (2): 285-292. 10.1016/j.metabol.2009.07.029. 19800084.
90. Zhang M. Lv X. Li J. Meng Z. Wang Q. Chang W. et al 2012. Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis. Mol. Cell. Endocrinol. 363 (1-2): 122-130. 10.1016/j.mce.2012.08.006. 22922125.
91. Zhang Y. Li X. Zou D. Liu W. Yang J. Zhu N. et al 2008. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J. Clin. Endocrinol. Metab. 93 (7): 2559-2565. 10.1210/jc.2007-2404. 18397984.
92. Zhao W. Xue R. Zhou Z.X. Kong W.J. Jiang J.D. 2008. Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis. Biomed. Pharmacother. 62 (10): 730-731. 10.1016/j.biopha.2008.01.007. 18337056.
93. Zhou J.Y. Zhou S.W. 2011. Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver. Fitoterapia, 82 (2): 184-189. 10.1016/j.fitote.2010.08.019. 20828602.
94. Zhou L. Yang Y. Wang X. Liu S. Shang W. Yuan G. et al 2007. Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism, 56 (3): 405-412. 10.1016/j.metabol.2006.10.025. 17292731.